Issue 5, 2019

Gasdermin D (GSDMD) as a new target for the treatment of infection

Abstract

The discovery of a previously unknown protein, gasdermin D (GSDMD), as the key effector that leads to pyroptosis and NETosis has created much excitement. Since its initial report in Oct. 2015, more than 200 papers have been published on studies of the structure and mechanism of GSDMD and its homologues. The clear connection between infection and inflammasome activation made GSDMD a promising target for the development of anti-infection treatment. In this mini review, we discuss first the current understanding of the structure and mechanism of GSDMD, focusing on its potential as a druggable target, and then recent efforts in the development of inhibitors to interfere with the pore-forming function of GSDMD and thus alleviate the detrimental effects due to pyroptotic cell death.

Graphical abstract: Gasdermin D (GSDMD) as a new target for the treatment of infection

Article information

Article type
Review Article
Submitted
31 Jan 2019
Accepted
04 Apr 2019
First published
04 Apr 2019

Med. Chem. Commun., 2019,10, 660-667

Author version available

Gasdermin D (GSDMD) as a new target for the treatment of infection

A. Pandeya, L. Li, Z. Li and Y. Wei, Med. Chem. Commun., 2019, 10, 660 DOI: 10.1039/C9MD00059C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements